UnipharLSE:UPR -4.15%84 ROA % is 4.14% as of Dec. 2025, which is 22% above its 10-year median of 3.39. GuruFocus rates LSE:UPR with a GF Score™ of 84/100 and a GF Value™ of £3.03 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 120 Medical Distribution companies, Uniphar ranks better than 64.17% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Uniphar's annualizedNet Income for the quarter that ended in Dec. 2025 was £59 Mil.
Uniphar's average Total Assets over the quarter that ended in Dec. 2025 was £1,420 Mil. Therefore, Uniphar's annualized ROA % for the quarter that ended in Dec. 2025 was 4.14%.
The historical rank and industry rank for Uniphar's ROA % or its related term are showing as below:
LSE:UPR'
s ROA % Range Over the Past 10 Years
Min: -0.36 Med: 3.39 Max: 5.37
Current: 3.26
During the past 10 years, Uniphar's highest ROA % was 5.37%. The lowest was -0.36%. And the median was 3.39%.
LSE:UPR's ROA % is ranked better than 64.17% of 120
companies
in the Medical Distribution industry
Industry Median: 2.23
vs LSE:UPR: 3.26
Uniphar (LSE:UPR) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Uniphar ROA % Related Terms
Uniphar ROA % Historical Data
* Premium members only.
The historical data trend for Uniphar's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Uniphar's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's ROA % distribution charts can be found below:
* The bar in red indicates where Uniphar's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Uniphar (LSE:UPR) has a ROA % of 4.14% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Uniphar and its competitors. This is 22% above median its historical median of 3.39. According to the industry distribution chart, Uniphar ranks #43 out of 120 companies in the Medical Distribution industry, placing it in the top 35.8%.
Is Uniphar's ROA % too high?
Uniphar's current ROA % of 4.14% is 22% above median its 10-year median of 3.39. The Medical Distribution industry median ROA % is 2.23. Uniphar's value of 4.14% is 85.7% above this industry median. Based on the distribution chart, Uniphar ranks #43 out of 120 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Uniphar has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's ROA % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Uniphar ranks #43 out of 120 companies for ROA %. This puts Uniphar in the upper half of its industry. The industry median ROA % is 2.23. Uniphar's value of 4.14% is 85.7% above this benchmark. While the company's 10-year median is 3.39 vs. the industry median of 2.23, Uniphar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.23, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current ROA % of 4.14% is 85.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median ROA % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current ROA % is 4.14%, which is 22% above median its own 10-year median of 3.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (LSE:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is £3.03, compared to a current price of £3.93 — trading 29.7% above its estimated fair value. The current ROA % is 4.14%, which is 22% above median its 10-year median of 3.39 and 85.7% above the Medical Distribution industry median of 2.23. Uniphar's overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Uniphar (LSE:UPR), the current ROA % is 4.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (LSE:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of £3.93 is trading 29.7% above its estimated GF Value™ of £3.03.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for LSE:UPR:
ROA %: 4.14% (22% above median its 10-year median of 3.39)
GF Value™: £3.03 vs. price of £3.93 (29.7% above fair value)
Industry Position: 85.7% above the Medical Distribution median (#43 of 120)
No single metric tells the full story. See the LSE:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
84GF Score
Get the complete analysis for LSE:UPR
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:UPR has been successfully added to your 
